HeartBeam received an FDA Breakthrough Device Designation for heart attack assessment. Read the noun: designation. It is not a clearance, and it is not an approval.
$BEAT is +75.75% at lunch on a $24M market cap. A designation moves a device into a faster lane for FDA interaction and review. The review itself still has to happen, and the headline gives no timeline for it.
This ticker has its own record. In 16 prior sessions, HeartBeam opened with a gap-up of 5% or more. 12 of those 16 closed below their open (75%), with a median open-to-close of -5.15%. That is this stock's history, not today's odds. A lunchtime print is also not the same thing as today's opening gap.
The crowd is paying for the stamp. The company announced a place in line.
Read what the designation actually covers. Then go eat lunch somewhere without a quote screen.